Clinical Trial Results: Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis [Phase 2]

View source ↗

Summary

A phase 2 placebo-controlled trial of brazikumab in moderately to severely active ulcerative colitis was terminated; results were posted after termination.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease
• Ulcerative Colitis

Drugs mentioned

• Brazikumab

Snippet

Sponsor: AstraZeneca | Conditions: Ulcerative Colitis, IBD | Phase 2 | Status: TERMINATED | Results posted: 2026-06-23